*3.1.4 Prostate cancer*

Wen et al. analyzed the m6A status using patient samples and bone metastatic patient-derived xenografts (PDXs) with prostate cancer through m6A high-throughput sequencing, and they found 4 credible m6A sites on lncRNA NEAT1-1. Besides, NEAT1-1 acted as a bridge to strengthen the combination between CYCLINL1 and CDK19 and promoted the Pol II ser2 phosphorylation in the promoter of RUNX2, leading to the development of bone metastatic prostate cancer [103]. By targeting ARHGAP1 and FAM134A, miR-940 boosted osteogenic differentiation of human mesenchymal stem cells [104]. miR-181b/Oncostatin m axis also contributes to prostate cancer bone metastasis by altering osteoclast differentiation [105]. To promote the bone-specific metastasis of prostate cancer, HOXA11-AS controlled the expression of chemokines, integrins, and associated genes like IBSP in collaboration with HOXB13 [106]. lncRNA PCAT6 enhances prostate cancer bone metastasis and tumor growth by upregulating IGF1R expression via increasing IGF1R mRNA stability through the PCAT6/IGF2BP2/IGF1R pathway [107]. lncRNA NEAT1/miR-205-5p/ RUNX2/SFPQ/PTBP2 axis and miR-378a-3p/ Dyrk1a/Nfatc1/Angptl2 axis are also devoted to bone metastasis [108, 109].
